Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

Diabetes prevalence shows a continuous increasing trend in South Asia. Although well-established treatment modalities exist for type 2 diabetes mellitus (T2DM) management, they are limited by their side effect profile. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) with their novel insulin-inde...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Indian J Endocrinol Metab
المؤلفون الرئيسيون: Kalra, Sanjay, Ghosh, Sujoy, Aamir, A. H., Ahmed, Md. Tofail, Amin, Mohammod Feroz, Bajaj, Sarita, Baruah, Manash P., Bulugahapitiya, Uditha, Das, A. K., Giri, Mimi, Gunatilake, Sonali, Mahar, Saeed A., Pathan, Md. Faruque, Qureshi, Nazmul Kabir, Raza, S. Abbas, Sahay, Rakesh, Shakya, Santosh, Shreshta, Dina, Somasundaram, Noel, Sumanatilleke, Manilka, Unnikrishnan, A. G., Wijesinghe, Achini Madushani
التنسيق: Artigo
اللغة:Inglês
منشور في: Medknow Publications & Media Pvt Ltd 2017
الموضوعات:
Review Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5240067/
https://ncbi.nlm.nih.gov/pubmed/28217523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.196029
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة